Methods and compositions for treating hypercholesterolemia
AssigneesTrustees of Boston University, KOS Pharmaceuticals, Inc.
InventorsVassilis Zannis, Kypreos Kyriakos
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for treating hypercholesterolemia using therapeutic apoE proteins. A therapeutic apoE protein is a naturally-occurring apoE protein (e.g., apoE1, apoE2, apoE2*, apoE2**, apoE3, and apoE4) that has one or more amino acid substitutions in the carboxy-terminal region which, when administered to a mammal having hypercholesterolemia, reduces the plasma cholesterol levels without inducing hypertriglyceridemia. The invention also provides a method for reducing plasma cholesterol using low doses of naturally-occurring apoE proteins.
Claims63
A method for reducing plasma cholesterol in a mammal, without inducing hypertriglyceridemia, said method comprising administering to said mammal a therapeutic apoE protein, wherein said therapeutic apoE protein comprises a naturally-occurring apoE protein having at least one amino acid substitution in the carboxy-terminal region.
A therapeutic apoE protein comprising a naturally-occurring apoE protein having at least one amino acid substitution in the carboxy-terminal region.
A method for reducing plasma cholesterol in a mammal, without inducing hypertriglyceridemia, said method comprising administering to said mammal an effective amount of a nucleic acid encoding a therapeutic apoE protein, operably linked to a promoter that, when expressed in the target cells, is capable of expressing said therapeutic apoE protein, and wherein said therapeutic apoE protein comprises a naturally-occurring apoE protein having at least one amino acid substitution in the carboxy-terminal region.
A nucleic acid encoding a therapeutic apoE protein comprising a naturally-occurring apoE protein having at least one amino acid substitution in the carboxy-terminal region.
A method treating hypercholesterolemia in a mammal comprising administering to said mammal a naturally-occurring apoE protein in an amount sufficient to reduce plasma cholesterol without inducing hypertriglyceridemia.
Dependencies are inferred from the claim text.